The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×7•Originally published 6 May 2026•Updated 6 May 2026•

1 min read

Novo Nordisk Raises 2026 Guidance Following Strong Q1 Profits and Wegovy Growth

Key Facts

1Novo Nordisk's adjusted operating profit reached DKK 32,858 million in the first quarter of 2026.

2The company raised its 2026 guidance for adjusted sales and growth driven by strong Wegovy performance and international operations.

28 days ago

Version History

Version 728 days ago

What changed: Updated the story to include the specific 12.5x TTM P/E ratio and identified new competitive threats from generics in China and India.

Version 628 days ago

What changed: Added critical context regarding adjusted revenue declines due to the exclusion of US 340B benefits and noted the stock's valuation discount relative to sector averages.

Version 528 days ago

What changed: Updated to confirm the raise in the full-year outlook for the current year, specifically linked to the strong Q1 earnings beat, alongside the 2026 guidance.

Version 428 days ago

What changed: The story was updated to include Q1 net sales of $15.2 billion, which significantly beat the $11.2 billion consensus, and to identify the NYSE ticker NVO.

Version 329 days ago

What changed: Updated to include the 9% stock price jump, revised percentage guidance ranges, detailed US weekly prescription data, and the timeline for international expansion.

Version 229 days ago

What changed: The story was updated to specify that the guidance hike is driven by the launch of the Wegovy pill form, which has already exceeded 2 million prescriptions.

Version 129 days ago

What changed: Updated the story to confirm that adjusted operating profit exceeded analyst forecasts.

Novo Nordisk shares surged after raising its financial outlook, reporting Q1 net sales of $15.2 billion that beat analyst forecasts. The NVO stock is currently trading at a historically low 12.5x TTM P/E ratio, highlighting a significant valuation discount despite its market leadership. However, the company faces rising competitive risks from Eli Lilly as well as generic alternatives emerging in the Chinese and Indian markets. The investment case remains supported by potential multiple expansion and the development of higher-dose versions of semaglutide. Looking ahead, the firm aims to launch an oral version of its weight-loss treatment in late 2026 pending regulatory clearance. Investors remain focused on whether the company can overcome global pricing and competitive pressures to close its current valuation gap.